KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Emergent BioSolutions (EBS) Goodwill: 2010-2022

Historic Goodwill for Emergent BioSolutions (EBS) over the last 13 years, with Dec 2022 value amounting to $218.2 million.

  • Emergent BioSolutions' Goodwill fell 2.98% to $218.2 million in Q2 2023 from the same period last year, while for Jun 2023 it was $218.2 million, marking a year-over-year decrease of 2.98%. This contributed to the annual value of $218.2 million for FY2022, which is 2.98% down from last year.
  • Per Emergent BioSolutions' latest filing, its Goodwill stood at $218.2 million for FY2022, which was down 2.98% from $224.9 million recorded in FY2021.
  • Emergent BioSolutions' Goodwill's 5-year high stood at $266.7 million during FY2020, with a 5-year trough of $218.2 million in FY2022.
  • Over the past 3 years, Emergent BioSolutions' median Goodwill value was $224.9 million (recorded in 2021), while the average stood at $236.6 million.
  • In the last 5 years, Emergent BioSolutions' Goodwill skyrocketed by 428.92% in 2018 and then decreased by 15.67% in 2021.
  • Yearly analysis of 5 years shows Emergent BioSolutions' Goodwill stood at $259.7 million in 2018, then climbed by 2.66% to $266.6 million in 2019, then climbed by 0.04% to $266.7 million in 2020, then fell by 15.67% to $224.9 million in 2021, then declined by 2.98% to $218.2 million in 2022.